Breakthroughs and challenges in the management of pediatric viral hepatitis

Table 2 Direct-acting antiviral regimens approved for treatment of chronic hepatitis C virus infection in children and adolescents

Regimen	Genotype and duration of treatment	Formulations	Dosage
Sofosbuvir/ledipasvir	GT 1, 4, 5, 6: 12 wk	Tablet (FDC) 400/90 mg	> 35 kg: 400/90 mg/d
	GT 1, treatment-experienced, cirrhosis: 24 wk		17-35 kg: 200/45 mg/d
			< 17 kg, older than 3 yr of age: 150/33.75 mg/d
		Tablet (FDC) 200/45 mg
		Pellets 200/45 mg and 150/33.75
Sofosbuvir + ribavirin	GT 2: 12 wk	Sofosbuvir: tablet 400 mg	Sofosbuvir: > 35 kg: 400 mg/d
	GT 3: 24 wk		17-35 kg: 200 mg/d
		Tablet 100 mg	< 17 kg, older than 3 yr of age: 200 mg if ≥ 17 kg
		Capsules 50 mg containing granules
			150 mg/d if < 17 kg. Ribavirin: 15 mg/kg per day in two divided doses
Sofosbuvir/velpatasvir	All GTs: 12 wkdecompensated cirrhosis: 12 wk + ribavirin	Tablet (FDC) 400/100 mg	> 30 kg: 400/100 mg/d
			17-30 kg, older than 6 yr of age: 200/50 mg/d. Ribavirin: 15 mg/kg per day in two divided doses
		Tablet (FDC) 200/50 mg
Glecaprevir/pibrentasvir	All GTs: 8 wk	Tablet (FDC) 100/40 mg/d	12-17 yr or > 45 kg: 300/120 mg/d
	All GTs, cirrhosis: 12 wk
	GT 3 treatment-experienced: 16 wk

FDC: Fixed-dose combination; GT: Genotype.